Fighting Covid-19 as soon as it enters the respiratory tract, that would be the objective of the nasal application. Since June 2020, the BioMAP research team of the UMR INRAE-University of Tours “Infectology and Public Health” (ISP), had been dedicated to the development of a nasal vaccine against the SARS-CoV-2 virus, supported by its research . by several university, academic and INRAE teams.
This Thursday, January 20, the researchers presented the results that demonstrate “the robustness of the concept of this vaccine by blocking any contagiousness to SARS-CoV-2”, indicates INRAE in a press release.
As the nostrils are the entry point for the virus, the immune mediators of nasal biomedicine will be able to act on the virus, prevent it from spreading through the body to prevent serious forms, but above all prevent it from spreading through coughing. or sneezes,” Professor Isabelle Dimier-Poisson, head of Biomap research at the University of Tours, told a news conference.
The results of this biomedicine were confirmed at the end of 2021 by new preclinical trials in rodents that validated its efficacy against the Delta variant. Therefore, the vaccine, which consists of the Spike protein, like mRNA vaccines, and non-mutated viral proteins, would provide protection against the SARS-CoV2 strain. According to Isabelle Dimier-Poisson, the second advantage of the nasal vaccine is based on its possible storage at 4°C, far from, for example, the -60°C and -90°C of the Pfizer vaccine.
production of tolosa
After encouraging preclinical trials, a fundraiser was awarded to the research team. In total, an endowment of 2.4 million has been allocated, of which 1.5 million from the Ministry of Higher Education, Research and Innovation and 0.9 million euros from the ANRS, “Emerging Infectious Diseases”, of the University of Tours. The objective is “to carry out the production of vaccine proteins in a GMP (Good Manufacturing Practices) environment, which is essential for human trials,” indicates INRAE.
Starting in the 1st quarter of 2022, the challenge will be to produce this biomedicine from the Toulouse company GTP Bioways and launch the production of clinical batches in the 2nd quarter with a view to human experimentation. The trials would lead to the marketing authorization of the vaccine at the end of 2023, beginning of 2024. The project could contribute to a way out of the pandemic crisis, at a time when the variants force the multiplication of vaccine reminders.
>> READ ALSO: Covid-19: a new vaccination center opens its doors on the Ramier Island in Toulouse
WeaPlay, WordPress Theme, Business Consulting Nulled, Avada 7.4 Nulled, Newspaper – News & WooCommerce WordPress Theme, Nulledfire, Elementor Pro Weadown, Astra Pro Nulled, Plugins, Rank Math Seo Pro Weadown, Woodmart Theme Nulled, Elementor Pro Weadown,Woodmart Theme Nulled, Wordfence Premium Nulled, Flatsome Nulled, Yoast Nulled, Woocommerce Custom Product Ad, Jannah Nulled, Dokan Pro Nulled, Fs Poster Plugin Nulled, Jnews 8.1.0 Nulled, PW WooCommerce Gift Cards Pro Nulled, Newspaper 11.2, Premium Addons for Elementor, Slider Revolution Nulled, Wpml Nulled, PHP Script, WP Reset Pro, Consulting 6.1.4 Nulled